New: Biosimilars strategies introduced.
Close
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
July 9, 2020 - Ipsen Biopharmaceuticals announced the FDA approval of Dysport (abobotulinumtoxinA), for the treatment of spasticity in patients 2 years of age and older.
Download PDF
Return to publications
